381 related articles for article (PubMed ID: 25857324)
1. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C
Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324
[TBL] [Abstract][Full Text] [Related]
2. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
3. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
[TBL] [Abstract][Full Text] [Related]
4. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097
[TBL] [Abstract][Full Text] [Related]
5. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
Mecha M; Feliú A; Iñigo PM; Mestre L; Carrillo-Salinas FJ; Guaza C
Neurobiol Dis; 2013 Nov; 59():141-50. PubMed ID: 23851307
[TBL] [Abstract][Full Text] [Related]
7. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.
Moreno-Martet M; Espejo-Porras F; Fernández-Ruiz J; de Lago E
CNS Neurosci Ther; 2014 Sep; 20(9):809-15. PubMed ID: 24703394
[TBL] [Abstract][Full Text] [Related]
8. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
9. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
Keating GM
Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
[TBL] [Abstract][Full Text] [Related]
10. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
[TBL] [Abstract][Full Text] [Related]
11. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
12. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
13. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Moreno Torres I; Sanchez AJ; Garcia-Merino A
Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
Sagredo O; Pazos MR; Satta V; Ramos JA; Pertwee RG; Fernández-Ruiz J
J Neurosci Res; 2011 Sep; 89(9):1509-18. PubMed ID: 21674569
[TBL] [Abstract][Full Text] [Related]
17. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
18. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
19. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]